Singapore/Sydney/Auckland/Greifswald: 27 Feb 2015 Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) is pleased to announce signing an exclusive agreement with RIEMSER Pharma GmbH (RIEMSER) of Berlin and Greifswald, Germany for the marketing and distribution of TEPADINA®, thiotepa infusion. Link and RIEMSER will collaborate to obtain marketing authority for the product in both countries.

Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 23/2/15. Specialist pharmaceutical company, LINK Healthcare (‘LINK’) is pleased to announce Australian orphan drug designation for para-amino salicylic acid (PAS) brand PASER®, indicated for use as part of an appropriate combination therapy for the treatment of multi-drug resistant tuberculosis. PASER® is part of Link’s portfolio through a long term relationship with specialist therapeutic

        – The product is a mercaptopurine oral liquid suspension for the treatment of Acute Lymphoblastic Leukaemia – ALLMERCAP™ is a child-friendly formulation offering more flexible, accurate & consistent dosing than the tablet form – LINK has partnered with Nova Laboratories to make the liquid suspension available in Australia   Sydney/Pretoria/Singapore/Hong Kong/Kuala